Treatment outcomes of extended-field radiation therapy and the effect of concurrent chemotherapy on uterine cervical cancer with para-aortic lymph node metastasis

Hong In Yoon; Jihye Cha; Ki Chang Keum; Ha Yoon Lee; Eun Ji Nam; Sang Wun Kim; Sunghoon Kim; Young Tae Kim; Gwi Eon Kim; Yong Bae Kim

doi:10.1186/s13014-014-0320-5

Table 4 Prognostic factors on overall survival and progression-free survival by Cox proportional-hazards model

From: Treatment outcomes of extended-field radiation therapy and the effect of concurrent chemotherapy on uterine cervical cancer with para-aortic lymph node metastasis

	Overall survival				Progression-free survival
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
Variables	HR (95% CI)	p value	HR (95% CI)	p value	HR (95% CI)	p value	HR (95% CI)	p value
Age (<50 vs. ≥50)	1.21 (0.59-2.51)	0.61			1.24 (0.69-2.21)	0.47
ECOG PS (0 vs. 1 or 2)	0.45 (0.22-0.95)	0.04	0.53 (0.25-1.12)	0.1	0.48 (0.27-0.87)	0.02	0.57 (0.31-1.03)	0.06
Tumor shape (exophytic vs. infiltrative)	1.75 (0.85-3.64)	0.13			1.75 (0.98-3.14)	0.06	1.67 (0.93-2.99)	0.09
Tumor size (<5 vs. ≥5 cm)	0.67 (0.3-1.47)	0.31			0.72 (0.39-1.33)	0.29
Parametrial involvement (no vs. yes)	0.4 (0.1-1.7)	0.22			0.5 (0.18-1.39)	0.18
Endocervical extension (others vs. yes)	1.85 (0.82-4.17)	0.14			1.47 (0.8-2.7)	0.22
Pelvic nodal involvement (no vs. yes)	0.78 (0.32-1.91)	0.58			0.71 (0.34-1.47)	0.35
Hydronephrosis (no vs. yes)	1.21 (0.42-3.5)	0.72			0.82 (0.4-1.65)	0.57
Stage (IB vs. IIB vs. IIIA-IVA)	Referent 0.38 (0.09-1.7)	0.45			Referent 0.45 (0.15-1.3)	0.32
Stage (IB vs. IIB vs. IIIA-IVA)	0.9 (0.42-1.92)				0.81 (0.44-1.49)
Radiotherapy duration (<10 vs. ≥10 weeks)	0.59 (0.28-1.23)	0.16			0.62 (0.35-1.12)	0.11
Doses to point A (<75 vs. ≥75 Gy)	0.87 (0.42-1.8)	0.71			0.64 (0.36-1.15)	0.14
Doses to PAN (<50.4 vs. ≥50.4 Gy)	1.09 (0.46-2.55)	0.85			0.75 (0.35-1.6)	0.45
Treatment period (<2000 vs. ≥2000)	1.25 (0.59-2.65)	0.56			0.98 (0.54-1.76)	0.95
Treatment response (CR vs. PR)	0.36 (0.16-0.81)	0.01	0.43 (0.19-0.98)	0.04	0.27 (0.14-0.51)	<0.001	0.3 (0.16-0.58)	<0.001
Concurrent chemotherapy (no vs. yes)	1.23 (0.59-2.54)	0.59			0.88 (0.49-1.57)	0.65

Abbreviation: ECOG PS Eastern Cooperative Oncology Group performance status, CR complete remission, PR partial response, HR hazard ratio, CI confidence interval.

Back to article page